Impact of ILM Peeling in RRD/ I-Peel

Sponsor
Berner Augenklinik am Lindenhofspital (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT04767555
Collaborator
(none)
250
1
2
39.2
6.4

Study Details

Study Description

Brief Summary

Retinal detachment is associated with a substantial risk of re-detachment in 10-20% and to the formation of secondary epiretinal membranes in up to 15%. Relevant postoperative vision loss is encountered in many instances, primarily in consequence of macular involvement, but also secondarily due to postoperative complications, namely the formation of an epiretinal membrane and proliferative vitreoretinopathy. These mechanical reasons of influence can potentially be prevented by ILM peeling during reattachment surgery. This, however, is not a generally accepted standard of care during primary routine vitrectomy.

Two groups suffering from primary retinal detachment will be compared: the first group will receive standard re-attachment vitrectomy surgery, whereas the second group will receive an identical vitrectomy surgery, but with additional ILM peeling. In this study, the investigators wish to assess the influence of ILM peeling on visual outcomes and postoperative complications over 12 months.

Condition or Disease Intervention/Treatment Phase
  • Procedure: ILM (inner limiting membrane) peeling
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
250 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Impact of ILM Peeling on Functional and Anatomic Outcomes of Vitrectomy for Primary Rhegmatogenous Retinal Detachment - the I-Peel Study
Actual Study Start Date :
Feb 23, 2022
Anticipated Primary Completion Date :
Apr 1, 2025
Anticipated Study Completion Date :
Jun 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: ILM (inner limiting membrane) peeling

ILM peeling adding to standard vitreous surgery in patients suffering from retinal detachment

Procedure: ILM (inner limiting membrane) peeling
The standard technique for the removal of the inner limiting membrane is a dye-assisted ILM peeling established since 20 years as the standard of care to treat vision loss due to epiretinal membranes or macular holes in eyes with an otherwise stable retina, but not during retinal detachment surgery. Other dyes may show a stronger staining effect but since there is evidence of a potential toxicity of ICG the investigators use the well-tolerated and for this purpose approved trypan blue dye Membrane Blue ® (Dorc). This intervention will be performed in addition to standard vitreoretinal re-attachment surgery.

No Intervention: No Peeling

standard vitreous surgery without ILM peeling in patients suffering from retinal detachment

Outcome Measures

Primary Outcome Measures

  1. Number of patients developing secondary epiretinal membrane formation [12 months]

    Clinically significant secondary epiretinal membrane formation requiring revision surgery

Secondary Outcome Measures

  1. Rate of re-detachments in patients [12 months]

    Revision surgery due to re-detachment independently of secondary epiretinal membrane formation

  2. Best-corrected visual acuity [12 months]

    Change in best-corrected visual acuity

  3. Complication rates [12 months]

    Intra- and postoperative complication rates including PVR

  4. Surgical times [minutes (0-300)]

    How long does the surgery take

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 110 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • primary rhegmatogenous retinal detachment

  • of legal age (18 years or older)

  • in case of bilateral retinal detachment, only the first-affected eye will be included

Exclusion Criteria:
  • pre-existing functional and morphological changes to the macula, hindering visual recovery (amblyopia, trauma, macular degeneration)

  • advanced retinal detachment with PVR stage C2 or more

  • eyes pre-operated within six months prior to the development of RD

  • state after any vitreoretinal surgery

  • state after complicated cataract surgery, including aphakia and anterior chamber lens implantation

  • patients with increased risk profiles

  • myopia magna (≥7 diopters)

  • advanced diabetic retinopathy

  • any chronic ocular or systemic inflammatory disease

  • any other proliferative systemic disease or condition associated with impaired wound healing

Contacts and Locations

Locations

Site City State Country Postal Code
1 Berner Augenklinik am Lindenhofspital Bern Switzerland 3012

Sponsors and Collaborators

  • Berner Augenklinik am Lindenhofspital

Investigators

  • Principal Investigator: Justus G Garweg, Prof. Dr., Berner Augenklinik am Lindenhofspital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Berner Augenklinik am Lindenhofspital
ClinicalTrials.gov Identifier:
NCT04767555
Other Study ID Numbers:
  • I-Peel 2021-00027
First Posted:
Feb 23, 2021
Last Update Posted:
Mar 16, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Berner Augenklinik am Lindenhofspital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 16, 2022